Revvity stock is underperforming, with a 26.7% drop from the 52-week high

From Yahoo Finance: 2025-06-24 11:13:00

Revvity, Inc. (RVTY) is a health science solutions provider valued at $11.2 billion, operating in Waltham, Massachusetts, with Life Sciences and Diagnostics segments. The company offers cutting-edge technologies in diagnostics, life sciences research, and applied markets, including imaging systems, reagents, software, and lab services.

Revvity stock has seen a 26.7% drop from its 52-week high of $129.50, with shares declining 11.5% over the past three months. Despite recent fluctuations, the stock has been trading below its 50-day and 200-day moving averages since early February.

Following the release of strong Q1 2025 results, Revvity saw a marginal increase in shares. Revenue reached $664.8 million, a 2.3% increase from the year-ago quarter, surpassing estimates. The company raised its full-year revenue guidance to $2.8 billion to $2.9 billion, boosting investor sentiment.

While Revvity underperformed compared to the Dow Jones, analysts remain moderately optimistic with a consensus rating of “Moderate Buy.” Despite this, shares are trading below the mean price target of $119.12. Labcorp Holdings Inc. (LH) has outpaced Revvity stock, soaring 13.8% YTD and 27.2% over the past 52 weeks.



Read more at Yahoo Finance: Is Revvity Stock Underperforming the Dow?